MS drug pricing not based on R&D costs, pharma execs say

(By Maia Anderson for Becker’s Hospital Review)

Though drugmakers often claim their prices are based on the cost of a drug’s research and development, a report published Nov. 25 in Neurology suggests corporate growth objectives and competition are what actually drive costs for multiple sclerosis drugs, according to STAT.   Continue reading article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or


Leave a Reply